1358099-18-9 manufacturers
- C25-140
-
- $68.00 / 1mg
-
2026-03-13
- CAS:1358099-18-9
- Min. Order:
- Purity: 98.81%
- Supply Ability: 10g
|
| | 1358099-18-9 Basic information |
| Product Name: | 1358099-18-9 | | Synonyms: | 1-(4-benzylpiperidin-1-yl)-3-(3,5-dimethyl-1-(3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl)propan-1-one;TRAF6-UBC13 INHIBITOR C25-140;1-Propanone, 3-[3,5-dimethyl-1-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-1-[4-(phenylmethyl)-1-piperidinyl]-;Ubiquitin conjugating enzyme,Ubiquitin ligase,Ubiquitin activating enzyme,C25 140,TNF Receptor,E3 ligating enzyme,C-25-140,E1/E2/E3 Enzyme,C25-140,C25140,Tumor Necrosis Factor Receptor,E2 conjugating enzyme,E1 activating enzyme,TNFR,inhibit,Inhibitor;1-(4-Benzylpiperidin-1-yl)-3-(3,5-dimethyl-1-(3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl)propan-1-one , C25-140;C25-140, 10 mM in DMSO | | CAS: | 1358099-18-9 | | MF: | C26H31N7O | | MW: | 457.57 | | EINECS: | | | Product Categories: | | | Mol File: | 1358099-18-9.mol |  |
| | 1358099-18-9 Chemical Properties |
| density | 1.29±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:62.5(Max Conc. mg/mL);136.59(Max Conc. mM) | | form | Solid | | pka | -0.22±0.30(Predicted) | | color | White to off-white |
| | 1358099-18-9 Usage And Synthesis |
| Uses | C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity[1]. | | in vivo | C25-140 (~1.5 mg/kg; topically to the shaved back and the right ear; twice daily for 6 days) ameliorates symptoms of autoimmune psoriasis in R 837-induced psoriasis mouse model[1].
C25-140 (6-14 mg/kg; given i.p.; twice daily for 14 days) shows a dose-dependent improvement of RA disease outcome in Collagen-induced arthritis (CIA) model[1].
C25-140 (10 mg/kg; i.v.) treatment shows that the Cmax, AUC, t1/2 and Vd are 9.7 μg/mL, 274083 ng min/mL, 80.62 min, and 4.13 L/kg, respectively[1].
C25-140 (10 mg/kg; p.o.) treatment shows that the Cmax, AUC, t1/2 and Vd are 3.4 μg/mL, 124034 ng min/mL, 127.33 min and 13.3 L/kg, respectively[1].
C25-140 (10 mg/kg; i.p.) treatment shows that the Cmax, AUC, t1/2 and Vd are 4.2μg/mL, 100000 ng min/mL, 184 min, 25.6 L/kg, respectively[1]. | Animal Model: | R 837-induced psoriasis mouse model (male BALB/c mice)[1] | | Dosage: | ~1.5 mg/kg | | Administration: | Topically to the shaved back and the right ear; twice daily for 6 days | | Result: | Showed a dose-dependent improvement of RA disease outcome. |
| Animal Model: | Collagen-induced arthritis (CIA) model in DBA1/J mice[1] | | Dosage: | 6 mg/kg, 10 mg/kg, 14 mg/kg | | Administration: | Given i.p.; twice daily for 14 days | | Result: | Ameliorated the arthritic index to almost baseline levels in this efficacy model at doses of 10 and 14 mg/kg. Dose-dependently improved symptoms of RA including inflammation and structural damage. |
| Animal Model: | BALB/C mice[1] | | Dosage: | 10 mg/kg | | Administration: | I.v. (Pharmacokinetic Analysis) | | Result: | The Cmax, AUC, t1/2 and Vd were 9.7 μg/mL, 274083 ng min/mL, 80.62 min, and 4.13 L/kg, respectively.
|
| | storage | Store at -20°C | | References | [1] Brenke JK, et al. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. J Biol Chem. 2018 Aug 24;293(34):13191-13203. DOI:10.1074/jbc.RA118.002649 |
| | 1358099-18-9 Preparation Products And Raw materials |
|